These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 16928883)
1. Comparison of human immunodeficiency virus type 1-specific inhibitory activities in saliva and other human mucosal fluids. Kazmi SH; Naglik JR; Sweet SP; Evans RW; O'Shea S; Banatvala JE; Challacombe SJ Clin Vaccine Immunol; 2006 Oct; 13(10):1111-8. PubMed ID: 16928883 [TBL] [Abstract][Full Text] [Related]
2. Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk. Farquhar C; VanCott TC; Mbori-Ngacha DA; Horani L; Bosire RK; Kreiss JK; Richardson BA; John-Stewart GC J Infect Dis; 2002 Oct; 186(8):1173-6. PubMed ID: 12355371 [TBL] [Abstract][Full Text] [Related]
3. Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women with a high risk of heterosexual acquisition of HIV infection. Novak RM; Donoval BA; Graham PJ; Boksa LA; Spear G; Hershow RC; Chen HY; Landay A Clin Vaccine Immunol; 2007 Sep; 14(9):1102-7. PubMed ID: 17671228 [TBL] [Abstract][Full Text] [Related]
4. Enhanced secretory leukocyte protease inhibitor in human immunodeficiency virus type 1-infected patients. Baqui AA; Meiller TF; Falkler WA Clin Diagn Lab Immunol; 1999 Nov; 6(6):808-11. PubMed ID: 10548568 [TBL] [Abstract][Full Text] [Related]
5. Differential mucosal susceptibility in HIV-1 transmission and infection. Moutsopoulos NM; Greenwell-Wild T; Wahl SM Adv Dent Res; 2006 Apr; 19(1):52-6. PubMed ID: 16672550 [TBL] [Abstract][Full Text] [Related]
6. Inhibitory function of secretory leukocyte proteinase inhibitor (SLPI) in human saliva is HIV-1 specific and varies with virus tropism. Skott P; Lucht E; Ehnlund M; Björling E Oral Dis; 2002 May; 8(3):160-7. PubMed ID: 12108760 [TBL] [Abstract][Full Text] [Related]
7. Anatomic dissociation between HIV-1 and its endogenous inhibitor in mucosal tissues. Wahl SM; Worley P; Jin W; McNeely TB; Eisenberg S; Fasching C; Orenstein JM; Janoff EN Am J Pathol; 1997 Apr; 150(4):1275-84. PubMed ID: 9094984 [TBL] [Abstract][Full Text] [Related]
8. Endogenous salivary inhibitors of human immunodeficiency virus. Shugars DC; Alexander AL; Fu K; Freel SA Arch Oral Biol; 1999 Jun; 44(6):445-53. PubMed ID: 10401522 [TBL] [Abstract][Full Text] [Related]
9. Endogenous mucosal antiviral factors of the oral cavity. Shugars DC J Infect Dis; 1999 May; 179 Suppl 3():S431-5. PubMed ID: 10099113 [TBL] [Abstract][Full Text] [Related]
11. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. McNeely TB; Dealy M; Dripps DJ; Orenstein JM; Eisenberg SP; Wahl SM J Clin Invest; 1995 Jul; 96(1):456-64. PubMed ID: 7615818 [TBL] [Abstract][Full Text] [Related]
12. Oral transmission of HIV, reality or fiction? An update. Campo J; Perea MA; del Romero J; Cano J; Hernando V; Bascones A Oral Dis; 2006 May; 12(3):219-28. PubMed ID: 16700731 [TBL] [Abstract][Full Text] [Related]
13. Human immunodeficiency virus type 1 stimulates the expression and production of secretory leukocyte protease inhibitor (SLPI) in oral epithelial cells: a role for SLPI in innate mucosal immunity. Jana NK; Gray LR; Shugars DC J Virol; 2005 May; 79(10):6432-40. PubMed ID: 15858026 [TBL] [Abstract][Full Text] [Related]
14. Salivary secretory leukocyte protease inhibitor increases in HIV infection. Lin AL; Johnson DA; Stephan KT; Yeh CK J Oral Pathol Med; 2004 Aug; 33(7):410-6. PubMed ID: 15250833 [TBL] [Abstract][Full Text] [Related]
15. The impact of pregnancy on anti-HIV activity of cervicovaginal secretions. Hughes BL; Dutt R; Raker C; Barthelemy M; Rossoll RM; Ramratnam B; Wira CR; Cu-Uvin S Am J Obstet Gynecol; 2016 Dec; 215(6):748.e1-748.e12. PubMed ID: 27393267 [TBL] [Abstract][Full Text] [Related]
16. HIV-1 neutralizing activity is correlated with increased levels of chemokines in saliva of HIV-1-exposed uninfected individuals. Hirbod T; Reichard C; Hasselrot K; Söderlund J; Kimani J; Bwayo JJ; Plummer F; Kaul R; Broliden K Curr HIV Res; 2008 Jan; 6(1):28-33. PubMed ID: 18288972 [TBL] [Abstract][Full Text] [Related]
17. Predominate HIV1-specific IgG activity in various mucosal compartments of HIV1-infected individuals. Lü FX Clin Immunol; 2000 Oct; 97(1):59-68. PubMed ID: 10998318 [TBL] [Abstract][Full Text] [Related]
18. Comparison of the distribution of IgG and IgA antibodies in serum and various mucosal fluids of HIV type 1-infected subjects. Raux M; Finkielsztejn L; Salmon-Céron D; Bouchez H; Excler JL; Dulioust E; Grouin JM; Sicard D; Blondeau C AIDS Res Hum Retroviruses; 1999 Oct; 15(15):1365-76. PubMed ID: 10515152 [TBL] [Abstract][Full Text] [Related]
19. Mucosal innate immune factors in secretions from high-risk individuals immunized with a bivalent gp120 vaccine. Cummins JE; Denniston M; Mayer KH; Pickard R; Novak RM; Graham P; Gurwith M; Orelind K; Ackers ML; Dezzutti CS AIDS Res Hum Retroviruses; 2007 May; 23(5):748-54. PubMed ID: 17531002 [TBL] [Abstract][Full Text] [Related]
20. Secretory IgA specific for MPER can protect from HIV-1 infection in vitro. Benjelloun F; Dawood R; Urcuqui-Inchima S; Rochereau N; Chanut B; Verrier B; Lucht F; Genin C; Paul S AIDS; 2013 Jul; 27(12):1992-5. PubMed ID: 23696073 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]